“‘Someday’ is Now!”: Anpac Bio & Med Partners Celebrate ‘National Cancer Prevention Month’ Surpassing 60,000 ‘Liquid Biopsy’ Cases
Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners and hospitals, are celebrating “World Cancer Day” (#WorldCancerDay) and “National Cancer Prevention Month” (#NationalCancerPreventionMonth) by surpassing a new, global milestone: processing over 60,000, independently-corroborated cases of Anpac Bio’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests worldwide.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005101/en/
Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)
World-renowned, Second Military Medical University and its affiliated Changhai Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and cancer-free control group blood samples, “blinded” to Anpac Bio, CH concluded CDA is a remarkably accurate, non-invasive test, supporting both early diagnosis, and monitoring treatment effectiveness, prognosis, and recurrence.
“Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for Lung Cancer and Esophageal Cancer than traditional tumor markers,” reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH Department of Oncology. “It (CDA) can also play a good role in complementing chest CT (Computerized Axial Tomography) screening for pulmonary nodules. The existing data suggests that CDA technology is a promising technology in the field of diagnosis and treatment assessment of Lung Cancer and cancer of the Esophagus.”
Described as “game changing” and receiving the “Breakthrough Innovation Award” at the World Nobel Prize Laureate Summit; and named “Most Promising Cancer Screening Company” at the 2017 Global Precision Medicine Industry Awards , Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.
By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.
Comprehensive research validity data from 60,000+ cases processed to date demonstrate CDA diagnostics consistently detects 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.
The Oncology Department of Shanghai Changzheng Hospital (SCH) corroborates these results. Since 2016, SCH has conducted two comprehensive clinical research studies of Anpac Bio’s CDA liquid biopsy technology. Submitting over 500 healthy “control” group; “high-risk” group (those genetically or environmentally pre-disposed to developing cancer); and independently-diagnosed and “confirmed cancer” group blood samples; for CDA analysis.
According to study director and SCH Deputy Professor Dr. Yuan Sheng Zang: “Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers. The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggest that CDA technology has a good prospect in the field of cancer diagnosis and prognosis.”
Pioneering liquid biopsy research (launched in 2008), Anpac Bio is already, fully-commercialized and generating revenue from Fortune 500 corporate, insurance, medical, research, and individual (“over the counter”) testing; while most competing “liquid biopsy” research remains in the laboratory and unavailable to the general public (for perhaps years).
Additionally, competing tests generally measure only single/few sample indicators (such as gene mutations that may indicate a patient’s increased risk or probability of potentially developing cancer at some point). Anpac Bio’s CDA is a “functional biology” test – providing medical professionals important information regarding actual disease signals present in the patient’s body at the moment of blood draw.
CDA’s independently-confirmed, very early stage cancer and pre-cancerous disease detection’s efficiency and accuracy is due to the technology’s multi-level and multi-parameter, patented design. With over 200 CDA-related patent applications worldwide (65+ currently issued), CDA’s integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals. By enhancing signal detection and processing, while reducing “noise”, the collected data is subsequently analyzed using Anpac Bio’s proprietary algorithms.
The resulting data is then assigned an overall value, called “CDA Value”, indicating cancer incidence risk level (the higher the CDA Value, the higher the cancer risk). CDA’s accuracy and advantages have been verified in previous studies, and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO), the Breast Cancer Symposium, and the World Nobel Prize Laureate Summit.
“Every day, our company hears of other, potential ‘liquid biopsy’ tests that report ‘someday’ may be used to catch cancer,” states Dr. Chris Yu, Anpac Bio Chief Executive Officer. “Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia’s most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We’re very proud that our CDA devices have advanced well-beyond the laboratory and are processing real tests for real people – saving lives every day. On this ‘National Cancer Prevention Month’, Anpac Bio and our medical partners want the world to know: ‘Someday’ is now!”
For more information about Anpac Bio please check: www.AnpacBio.com.
Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Nearly 1 Billion People Worldwide Have Sleep Apnea, International Sleep Experts Estimate21.5.2018 18:15 | Pressemelding
A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conference indicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005096/en/ Woman wearing CPAP, the gold standard treatment for sleep apnea (Photo: Business Wire) The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacte
Pietro Rosa TBM Signs Long-Term Agreement with Pratt & Whitney21.5.2018 15:13 | Pressemelding
Pietro Rosa TBM (Turbine Blade Manufacturing) today announced that it has signed a 10-year, long-term agreement (LTA) with Pratt & Whitney, a division of United Technologies Corp., to supply airfoil products for both commercial and military engines. The LTA, which may extend to the entire Pietro Rosa TBM Group in Europe and the United States, will support Pratt & Whitney’s F135, PW2000 and the Geared Turbofan™ (GTF) family of engines. This agreement represents a significant step in the collaboration between the two companies, enabling the Pietro Rosa TBM Group to utilize its advanced engineering capabilities and the vertical integration of hot forming, machining and surface finishing technologies. “We’re pleased to sign this agreement with Pietro Rosa,” said Art Erikson, executive director of Strategic Sourcing, Pratt & Whitney. “We have tremendous growth ahead, and suppliers like Pietro Rosa that sign up to our contractual governance, commitment to cost competitiveness and continuous
NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00 | Pressemelding
NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip
Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00 | Pressemelding
Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior
Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27 | Pressemelding
At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00 | Pressemelding
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba